Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06176261 · ClinicalTrials.gov registry record · Phase 2
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
A Phase 2 study of Breast Cancer and HER2-Negative Breast Cancer, sponsored by Sarah Sammons, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
- 3
- Study locations
NCT06176261: Recruiting Phase 2 study of Breast Cancer and HER2-Negative Breast Cancer, sponsored by Sarah Sammons, MD.
NCT06176261 is a Phase 2 study of Breast Cancer and HER2-Negative Breast Cancer that is actively recruiting participants, run by Sarah Sammons, MD. The registered enrollment target is 58 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06176261, a Phase 2 study of Breast Cancer and HER2-Negative Breast Cancer, is actively recruiting participants, sponsored by Sarah Sammons, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugate)
Primary Outcome
The objective response rate (ORR) was defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RANO-BM criteria defined protocol section 11.1.1.
Conditions Studied
Interventions
- DRUG Datopotamab Deruxtecan
Study Locations (3)
Florida
- Miami Baptist Cancer Institute/ - Miami
Massachusetts
- Dana-Farber Cancer Institute - Boston
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2024-01-08 |
| Est. Completion | 2029-01-01 |
| Phase | Phase 2 |
What NCT06176261 shows while recruiting
NCT06176261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Datopotamab Deruxtecan is the first listed.
NCT06176261 reports a single indexed study location in Florida, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT06176261 about?
NCT06176261 is a clinical study titled "DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs". The purpose of this study is to test the safety and effectiveness of the study drug datopotamab deruxtecan in participants with metastatic breast cancer that has spread to the brain. The name of the study drug used in this research study is: Datopotamab deruxtecan (a type of antibody-drug conjugat...
What is the current status of trial NCT06176261?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2024-01-08. Estimated completion is 2029-01-01.
What conditions does trial NCT06176261 study?
This clinical trial studies the following conditions: Breast Cancer, HER2-Negative Breast Cancer, Breast Cancer Female, Metastatic Triple-Negative Breast Carcinoma, HER2-Negative Breast Carcinoma.
What interventions are being tested in trial NCT06176261?
The interventions under investigation include: Datopotamab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06176261?
This trial is sponsored by Sarah Sammons, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06176261 being conducted?
This trial has 3 study locations across Florida, Massachusetts, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06176261's enrollment target sits among peer trials
58 761st of 1224 higher than 461 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI